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  ABSTRACT 
 
EARLY ONSET MARIJUANA USE AND ADULT MENTAL HEALTH 
 
By 
 
Christine Murphy Andrews 
 
April 11, 2016 
 
 
  
 
INTRODUCTION:  The impact of marijuana use has become a national topic with the increase in state’s 
legalizing or decriminalizing the use of the drug. To understand the impact this new trend may have on the 
population, it is necessary to characterize the interaction between marijuana use and health outcomes. 
Previous research has focused on the acute effects of marijuana on mental health and longitudinal impacts of 
marijuana use in the adolescent population. However there are no previously published studies on the 
impact of early onset marijuana use on adult mental health. 
  
AIM: This study aims to determine the prevalence of early onset marijuana use and if there is a statically 
significant association between early onset marijuana use (<14 years old) and increased prevalence of 
adverse mental health outcomes in adult life. 
  
METHODS: This study was conducted using data from the 2014 National Survey on Drug Use and Health. The 
study population included 41, 285 participants 18 or older at the time of the cross-sectional survey. Adult 
mental health outcomes were modeled for both early onset marijuana users and non-early onset marijuana 
users using a multiple logistic regression model to calculate both adjusted and unadjusted odds ratios (AOR’s, 
OR’s) with 95% confidence intervals. Statistical analysis was performed to examine the association between 
early onset marijuana use and negative adult mental health outcomes including serious mental illness, any 
mental illness and lifetime depressive episodes. 
  
RESULTS:  This study found that in adults aged 18 and older the prevalence of early onset marijuana use was 
8.3%. The prevalence of early onset marijuana use varies by gender, with a prevalence of 5.1(95% CI 4.7-5.2) 
for males and 3.3(95% CI 3.1-3.5) for females. Early onset marijuana use had a statistically significant 
association with all three indicators of poor adult mental health. The AOR for early onset marijuana use and 
serious mental illness was 2.3(95% CI 1.972-2.758). The association between early onset marijuana use and 
adult depressive episode had an AOR of 2.1(95% CI1.906-2.389). 
  
DISCUSSION: These findings suggest that early onset marijuana use is a risk factor for adverse mental health 
outcomes in adulthood. Consistent with findings from other nationally representative surveys, the prevalence 
of early onset marijuana use is higher in males than females. Early onset marijuana use is associated with 
increased odds of past year serious mental illness and past year any mental illness. This suggests that 
legislature considering marijuana legalization must also consider policies addressing under age use of the 
drug. Further longitudinal research is needed to father assess the association between early onset marijuana 
use and adult mental health. 
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1. Introduction 
 
1.1 Background 
 
The impact of the use of marijuana or cannabis has become a topic of popular debate as 
states begin to shift towards legislature legalizing or decriminalizing the sale of the drug.  While 
marijuana has existed in the United States since the American Revolution as a byproduct of the 
hemp trade, it was not until the early 20th century that Mexican immigrants introduced the use 
of marijuana as a recreational drug1,2. Similar to opiates and cocaine, marijuana was available 
both from pharmacies and over the counter. Alongside the cultural shift of Prohibition, states 
began outlawing marijuana and by 1925, 26 states had passed laws prohibiting its sale3. 
Marijuana became a Schedule I drug with the passing of the federal Controlled Substances Act 
in 19703. Schedule I drugs meet the following criteria: high potential for abuse and no current 
justification for medical use4 Possession and sales of Schedule I drugs is classified as a federal 
felony. 
Over the last decade, multiple states have begun introducing legislation to either allow 
the direct sale of marijuana, decriminalize possession of the drug or allow the drug to be used 
for medicinal purposes2. Unlike pharmaceuticals, relatively few clinical trials have been 
conducted on the medicinal use of marijuana leading to a lack of knowledge in the potential 
health benefits or harm as well as correct dosing and potency levels3. Past research on 
marijuana has focused on the impacts of its recreational use and prevalence primarily from a 
cross-sectional view. Within the job setting, marijuana use has been linked to higher rates of 
absenteeism and occupational injuries5. In adolescents, marijuana has been associated with a 
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higher likelihood of dropping out of school, decreased academic performance and a drop in IQ 
over time6,7. While numerous associations between marijuana use and poor health outcomes 
have been established, there is a lack of data on the effects of early marijuana use on adult 
mental illness8. Additionally, while many studies have linked marijuana use to an increase in 
psychosis, few have examined the impact of marijuana on less acute mental illness in the adult 
population9. This study will focus on determining if there is an association between early onset 
marijuana use and mental health outcomes in adult life, using data from the SAMHSA NSDUH 
2014 public-access file. 
 
1.2 Research Questions 
1. What is the prevalence of early onset marijuana use in the United States population? 
2. Does the prevalence of early onset marijuana use vary between men and women? 
3. Is there an association between early onset marijuana use (<14 years old) and adverse 
mental health outcomes in adult life? 
 
1.3 Research Aims  
This study aims to determine the prevalence of early onset marijuana use and if there is 
a statically significant association between early onset marijuana use (<14 years old) and 
increased prevalence of adverse mental health outcomes in adult life. 
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1.4 Research Hypotheses  
Ha: Adults who reported first onset of marijuana use before the age of 14 years old will 
have an increase in adverse mental health outcomes in their adult life.  
 
Ho: Adults who reported first onset of marijuana use before the age of 14 years old will 
not have an increase in adverse mental health outcomes in their adult life.  
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2. Review of the Literature 
 
2.1 Marijuana 
 Marijuana or cannabis is an illicit drug derived from the dried flowers, stems and leaves 
of the Cannabis sativa, or the hemp plant4. Marijuana is most commonly found as a shredded 
dry mixture resembling tobacco, but can also be in an oil or resin form4.  The drug is typically 
smoked, ingested in a food, or used as a tea. The use hand-rolled cigarettes (joints), pipes and 
water pipes (bongs) are the most common ways to smoke marijuana3. The effects of marijuana 
depend on many different factors including the dose used, the method of use, the setting of 
use, the user’s previous experiences with cannabis and the expectations of the user10. The 
effects of cannabis range from euphoria, relaxation, and perception changes including the 
intensification of sense such as smell and taste11. The majority of marijuana users report that 
they use in order to achieve this “high” and the increased sociability it provides when used in a 
group context. The marijuana ‘high” has an onset about 30 minutes after a cannabis dose is 
taken and lasts for about 1 to 2 hours3.  
 Marijuana’s active agent is the chemical delta-9- tetrahydrocannabino, known as THC3. 
THC is a psychoactive chemical affecting the mind and the body through ingestion or inhalation. 
THC impacts the cannabinoid receptors in the brain when it attaches to them after initiation 
through the bloodstream. The activity of nerve cells is impacted by THC including receptors for 
memory, pleasure, thought, coordination, concentration and temporal ability. This leads to 
short terms effects such as memory-loss, disabled perception, difficulty in concentration and 
learning and loss of coordination3. Long-term marijuana use can lead to physical dependence 
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and withdrawal symptoms after discontinuation. Recent studies have shown that marijuana is 
more addictive than previously believed, with 1 in 11 or 9% of cannabis users becoming 
dependent at some point in their lifetime12,13.  
Marijuana use has also been linked to physical symptoms and disease. Similar to 
smoking, marijuana use leads to an increased risk of cancers of the head, neck, lungs and 
respiratory tract due to the carcinogens and toxins inhaled during use1.  Other respiratory 
health problems marijuana smokers are at risk for include asthma, emphysema and COPD14. 
Marijuana use during pregnancy has been associated with delays in fetal development and low 
birth weight. Preliminary research also suggests that marijuana use during pregnancy can 
contribute to the risk of rare forms of cancer in the child including neuroblastoma15. 
Additionally research has shown an association between prenatal marijuana use and 
malformation in the neurological pathways moderating the emotional functioning of the 
fetus16. 
 
Impact on the Brain  
A large amount of animal research has focused on the direct impact that marijuana has 
on the brain and neurological system through the dopamine pathways. Dopamine, a 
neurotransmitter in the brain, impacts movement, motivation, reward and addiction. Most 
addictive drug use increases dopamine in the brain, flooding the dopamine pathways and 
engaging the pleasure seniors and positive feedback loop17.  Studies on the impact of marijuana 
on the release of dopamine in the human brain are mixed. Two recent studies reported an 
increase in dopamine in the human brain after cannabis use18,19. Conversly, a recent study on 
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the impact of recreational doses of marijuana concluded that recreational cannabis use does 
not release significant amounts of dopamine into the brain20. A systematic review examined 
and evaluated studies on the impact marijuana has on dopaminergic signaling in the human 
brain. While some studies showed hat the active agent of marijuana, THC, has been associated 
with increased levels of dopamine in the brain, other studies concluded there is no impact from 
marijuana use on dopamine pathways 21.  The review concluded that more research is needed 
into the actual effects marijuana has on the human brain because of conflicting study reports 
and a lack of standardization in the research methods used across the studies reviewed. Recent 
studies cited in the systematic review suggested that while there is little evidence to support 
that acute marijuana use impacts the dopamine receptors in the human brain, chronic 
marijuana use reduces both dopamine synthesis and dopamine release capacity22.  
   
Marijuana Prevalence  
 Marijuana has grown to become the most popular and widely spread illicit drug in the 
United States. Results from the 2013 National Survey on Drug Use and Health (NSDUH) find that 
19.8 million or 7.5% of persons aged 12 or older were current users of marijuana, an increase 
from a rate of 5.8% in 200223. Marijuana was the most reported illicit drug of current use for all 
age categories, with young adults having the highest prevalence rates of current marijuana use 
at 19.1% (Abuse, n.d.). The rate of current use of marijuana was higher in males(7.9%) than 
females(6.2%).  The daily use of marijuana has rapidly increased in the U.S. with 5.7 million 
persons aged 12 or older reporting daily use in 2013 compared to 3.1 million reporting daily use 
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in 2006. The amount of daily or almost daily users in the U.S. represented 41.1%  of marijuana 
users.  
 Marijuana dependence continues to contribute to the burden of disease in the United 
States. In 2013, 4.2 million persons reported marijuana dependence or abuse. The rate of 
marijuana dependence or abuse has remained similar from 2002(1.8%) to 2013(1.6%).  
Marijuana related medical emergencies have increased 21% from 2009 to 2011, with 456,000 
marijuana related medical emergencies reported in 20112. Currently, little research has been 
done on the cause of the increase-it is unknown whether it is due to increased marijuana 
potency, increased use of marijuana or other factors. Some studies have found a recent 
increase in the potency of THC content in marijuana being sold in the United States, suggesting 
that new users may experience a high risk for adverse effects during use24. 
  
2.2 Mental Health  
 Mental health and its impact on the global burden of disease is a relatively new focus of 
public health interest. Historically, mental health disorders have not been a health priority, 
both globally and nationally, with little funding being allotted for the study and treatment of 
behavioral health disease. Prevalence and incidence rates for mental health disorders have 
been difficult to obtain due in part to a lack of reporting and little to no mental health resources 
available to diagnose and treat psychiatric diseases25. Typically healthcare services for mental 
health disorders have been segregated from the larger pool of healthcare resources, falling 
behind both communicable and chronic disease.  
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Research in the last 15 years has begun to gain a better perspective on the prevalence 
of mental health disorders at the population level. In the most recent prevalence study (when) 
conducted by the National Institute of Mental Health (NIMH), the prevalence of any mental 
illness(AMI) among U.S. Adults is 18.1%26. The NIMH defines “Any Mental Illness” as a mental, 
behavioral or emotional disorder that meets DSM-IV criteria and has been diagnosed within the 
past year26.  The NIMH reports that serious mental illness (SMI), or mental illness that results in 
serious functional impairment has a prevalence of 4.2% representing about 9.8 million adults in 
the U.S27.  
 With the shift in focus from the burden of disease mortality to the burden of disease 
morbidity, mental health disorders have begun to receive attention. The burden of mental 
health disorders far outweighs its allocated recourses, both internationally and within the 
United States. The true costs of mental health disorders are hard to determine due to various 
under identified key components28. Economically, mental health disorders create a cost burden 
in indirect costs such as loss of productivity, loss of income, and cost of social support in 
addition to upfront costs for diagnosis and treatment. Similar to rising healthcare costs due to 
chronic disease, the burden of mental health disorders falls on the population as a whole.  
 There are multiple reports on the monetary costs of mental health illness both globally 
and within the U.S. The Agency for Healthcare Research and Quality (AHRQ) reported mental 
disorders as one of the top five most costly conditions in terms of direct medical spending, 
rising in costs from $35.2 billion to $57.5 billion over a 10 year period29. It is estimated that 
persons with serious mental illness that an individual reduction of earnings of $16, 306 in a 12 
month period, which generalizes to an annual loss of $193.2 billion in the U.S. general 
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population per year28. The World Health Organization (WHO) recently estimated the global cost 
of mental health disorders to be $2.5 trillion with a projected increase to $6 trillion by 203030.  
 
Anxiety 
 The most frequent mental health disorder addressed in the primary care setting is 
generalized anxiety disorder. Generalized anxiety disorder is categorized by  anxiety, tension 
and psychosomatic symptoms such as sleep disturbances and weight loss that persist for 6 
months of longer31. A systematic review of the prevalence and incidence literature for anxiety 
disorders internationally concluded that the best estimate for prevalence of 1-year and lifetime 
prevalence of all anxiety disorders was 10.6% and 16.6% respectively32, The prevalence of 
generalized anxiety disorder was found to be 2.6% for 1-year prevalence and 6.2% for lifetime 
prevelence32. The small ratios between 1-year and lifetime prevalence of both all anxiety 
disorders and generalized anxiety disorder seems to suggest that the majority of people 
experience anxiety disorders on a continuous or reoccurring basis.  
 The prevalence of anxiety disorders in the United States continues to be the highest of 
any mental health disorder in recent surveys. The 2005 National Comorbidity Survey reported a 
lifetime prevalence of 28.8% for any anxiety disorder in the United States33. The age category of 
30 to 44 years old reported the highest anxiety lifetime prevalence at 35.1% , while 18 to 29 
and 45 to 59 reported a lifetime prevalence of 30.2% and 30.8%, respectively33. Older adults(60 
and above) reported much lower rates of anxiety, with a lifetime prevalence of 15.3%33. A study 
of gender differences and anxiety disorders in the United States concluded that the lifetime and 
1-year prevalence ratios between males and females were 1:1.7 and 1:1.79, respectively34 
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 Few studies have been done recently on the economic costs of anxiety disorders both 
globally and in the United States. In the 1990’s the economic costs of anxiety disorders in the 
United States were estimated to be 42.3 billion a year, approximately one-third of the S148 
billion spent annually on healthcare35. A more recent study on the cost of mental health 
disorders in Europe found that anxiety disorders accounted for €74.4 billion of a total of 
€798billion spent on brain disorders in 201036.  
 
Depression  
 Depression is one of the most common mental health disorders in the world and is 
characterized by feelings of intense sadness, lack of appetite, loss of sleep and in severe cases 
thoughts and actions of suicide37. Currently, the WHO estimates that globally, 300 million 
people suffer from depression37. Additionally, the WHO categorizes depression as the third 
most important cause of disease burden in their 2004 report on the burden of global illness38 A 
recent study on the occurrence of depression across cultures concluded that while lifetime 
prevalence of depression was greater in high income countries than low or middle income 
countries, 1-year prevalence of depression had no significant difference39. 
 A recent study of lifetime prevalence of mental health disorders in the United States 
concluded that depression has a lifetime prevalence of 16.6%33. The highest lifetime prevalence 
of depression was in the 30 to 44 age range with a prevalence of 19.8%33. The 45 to 59 and the 
18 to 29 age ranges reported lifetime prevalence’s of 18.8% and 15.4%, respectively33. Again, 
older adults reported the lowest lifetime prevalence of depression at 10.6%33. The National 
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Institute of Mental Health report a 1-year prevalence of adult major depression as 6.6%40. The 
prevalence of major depression is higher in females than males at 8.2% and 4.8%, respectively40 
 The economic costs attributed to depression by the WHO are the highest out of any 
mental disorder. In the US, depression accounts for 3.75% of all DALYs and 8.3% of years lived 
with disability (YLDs)41. Recently, the WHO classified depression as the fourth leading cause of 
disability globally and projected that by 2020 it will become the second leading cause of 
disability42 Several studies have quantified the equivalent monetary loss attributed to days of 
work missed due to depression, with ranges from $30.1 billion to $55.5 billion42. Economic 
costs of depression have increased in the US by 21.5% ($173.2 billion to $210.5 billion) between 
2005 and 201043  
 
2.3 Mental Health and Marijuana Use  
 Marijuana use has long been associated with outcomes related to mental health status 
in both adults and adolescents including depression, anxiety and psychosis14. Current research 
has yielded conflicting results on whether incidence of mental disorders increases with 
marijuana use. A recent study of US high-school students found that when controlling for social 
economic status (SES), chronic marijuana use was still associated with poor mental health6. 
Additionally, the study found that the association became insignificant when controlling for the 
use of tobacco and alcohol, suggesting a difficulty in identifying the impact of marijuana versus 
that of tobacco and alcohol. 
 A cohort study of young adults recruited their freshman year of college examined the 
association between marijuana use in college and mental health outcomes 10 years post-
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matriculation. The study separated the cohort into groups describing their trajectory of 
marijuana use which included Non-Use, Low-Stable, Early-Decline, College-Peak, Late-Increase 
and Chronic. The study found that both the Late-Increase and Chronic group of marijuana users 
reported significantly lower mental health 10 years post-matriculation than the other groups8. 
 A cross-sectional interview study of young adults (18-30) examined the association 
between the level of marijuana use and mental health disorders. The sample included 1, 072 
non-users and 521 users of which 252 were categorized as marijuana dependent and 269 were 
not44. The study concluded that both dependent and non-dependent users have higher odds of 
having mood disorders compared to the general population (OR 17.75 p<0.001 and 8.91 
p<0.001 respectively)44 When adjusted for childhood adversity and other substance use, the 
dependent marijuana group have significantly higher odds of having a mental health disorder 
than the non-dependent group(OR=2.40 p<0.001)44.  
 
Anxiety 
 A cohort study of adolescent Australians that followed participants until the age of 29 
years concluded that daily use of marijuana contributed to the development of anxiety 
disorders in young adults. A cohort of adolescents (mean age 14.9–17.4 year) with a sample size 
of 1,943 were followed over a span of 15 years in their late 20’s.  Both daily and weekly users in 
adolescence had higher OR’s of having an anxiety disorder at 29 years old, OR 2.5 and 3.2 
respectively45.  
 A systematic review of literature on the association between marijuana use and anxiety 
disorders examined 16 studies. High frequency marijuana users were found to have a higher 
 13 
 
rate of anxiety disorder, while those with anxiety disorders were also found to have a higher 
rate of marijuana use46. The directionality of the association between marijuana and anxiety 
was unable to be determined through review of the literature.  
 A meta-analysis of 31 studies examined the association between marijuana use and 
anxiety. The 31 studies drew from 10 countries and 112, 000 noninstitutionalized partisans47 In 
the analysis a positive association was found between marijuana use and anxiety(OR = 1.24, 
95% CI: 1.06-1.45, p = .006; N = 15 studies) and marijuana use disorder and anxiety(OR = 1.68, 
95% CI: 1.23-2.31, p = .001; N = 13 studies)47. Additionally, the comorbidities of depression and 
anxiety were positively associated with cannabis use47. These findings suggest that heavy and 
chronic marijuana use that needs treatment is more likely to be associated with anxiety than 
non-disordered marijuana use.  
   
Depression  
 A cross-sectional study of adults using Wave I of the National Epidemiologic Survey on 
Alcohol and Related Conditions (NESARC-I) examined the association between marijuana use 
and depression stratified by gender. The study divided partisans with depressive disorders 
(N=3416) into categories determined by their marijuana use. The categories included no use, 
occasional use and regular use of marijuana over the past year. The Quality of Life 
questionnaire was used to assess depression. Overall the study found that women who were 
regular cannabis users reported a high score on the depression scale, while men had no 
significant differences between users and non-users48. 
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 A longitudinal study of young adult (18-24) women in Rhode Island examined the 
change in depression symptoms relative to marijuana use. The partisans (n=332) were 
randomly chosen from a clinical trial of a marijuana intervention for sexually active, young adult 
females.  After controlling for alcohol use, the study found that there was a positive association 
between a reduction in marijuana use and a reduction in depression symptoms. Both those 
who reported mild(b=−0.26; 95% CI:−0.44,−0.08; P=.004) and moderate/severe depression (b = 
−0.50; 95% CI: −0.68,−0.33; P < .001) had significant reductions in symptoms with a reduction in 
marijuana use49. 
 A meta-analysis of longitudinal studies of the association between marijuana use and 
developing depression examined data from 14 studies. The total number of subjects included in 
the qualitative analysis was 76, 05850.  Positive associations with developing depression were 
found for both regular and heavy marijuana use. Regular marijuana users had an OR of 
1.17(95% CI 1.05-1.30) for developing depression when compared with non-users, while heavy 
marijuana users had an OR of 1.82(95% CI 1.21–2.16) when compared with non-users50.  
 
2.4 Early Onset Marijuana Use  
 Multiple federal national surveys have monitored the use of marijuana in adolescents 
since the late 1970’s. The Monitoring the Future survey, collects an annual, representative 
sample of public and private secondary school students in the United States. Beginning in 1975, 
the survey collected data from 12th graders and in 1991 began to collect data from grades 8, 10 
and 12. Administered by the University of Michigan, it is supported with grants by the National 
Institute on Drug Abuse. In the most recent marijuana use prevalence data from the Monitoring 
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the Future study, lifetime use prevalence for grades 8, 10 and 12 were 15.6%, 33.7% and 44.4%, 
respectively, in 201451.  Current marijuana use, defined as use in the past 30 days, was 6.5% for 
8th grade, 16.6% for 10th grade and 21.2% for 12th grade51. The prevalence of daily use of 
marijuana for grades 8, 10 and 12 combined was 3.3% in 2014. When broken down by grade 
level, daily marijuana prevalence rates were 1.0%, 3.4% and 5.8%, respectively51. The 
Monitoring the Future study does not collect data on age of initiation of marijuana use. 
 The National Survey on Drug Use and Health (NSDUH), the survey being used for this 
thesis, is a nationally representative sample of the noninstutionalized United States population 
age 12 and older. More information on the methodology of this annual survey can be found in 
the Methods section of this paper. Data from the 2013 NSDUH on early onset marijuana use 
reports that the prevalence of current marijuana use (past 30 days) was 7.1% in youth ages 12 
to 17. When stratified by gender, past month marijuana use for ages 12 to 17 was higher in 
males at 7.9%, compared to females at 6.2% for 2013. When stratified by age, past month 
marijuana use prevalence was 1.0% for ages 12 or 13, 5.8% for ages 14 or 15 and 14.2% for ages 
16 or 17. The NSDH had no reported data on the daily use of marijuana in the age group 12 to 
17 years, although it does ask survey questions about age at first use of marijuana.  
 The Youth Risk Behavior Surveillance System (YRBSS) also collects annual data on the 
use of marijuana in youth in grades 9 to 12. The YRBSS is a cross-sectional survey designed and 
administered annually by the Centers for Disease Control and its state partners. While there is a 
middle school version of the YRBSS, which surveys students in the age group of interest to this 
thesis, the middle school survey is not nationally representative at this time and is only 
available at the state-level estimate52. The most recent YRBSS data from the 2013 survey 
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reported a national lifetime prevalence of marijuana use as 40.7%53. For males and females the 
lifetime marijuana use prevalence was 42.1% and 39.2% respectively54. 23.4% of high school 
students reported currently using marijuana (in the past 30 days), with 25.0% of males 
reporting current use compared to 21.9% females53. Early onset marijuana use captured as 
having tried marijuana before the age of 13 had a reported prevalence of 8.6%, with 11.1% and 
6.2 for males and females respectively54. 
 
2.5 Conclusion  
 The purpose of this research study is to assess whether early onset marijuana use is 
correlated with negative mental health outcomes in adult life. While the prevalence of 
marijuana use in youth ages 12 to 17 is widely monitored and reported in the United States, 
there are few studies outside of the Youth Risk Behavior Surveillance System that collects data 
on the age of initiation of marijuana use. Previous studies have found associations between 
marijuana use and poor mental health outcome such as anxiety, depression and psychosis45–
50,55,56. This thesis will expand on previous research that examined the association between 
marijuana use and mental health by focusing on a subset of marijuana users (early onset users) 
and their mental health outcomes in their adult life. An understanding of the relationship 
between early onset marijuana use and mental health in adult life can help behavioral health 
clinicians identify those who are at a higher risk for poor mental health outcomes and target 
individualized interventions to such a population. Focusing on early onset users of marijuana 
(<14 years) assess an at risk population that if often missed in survey’s of high school drug use. 
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Additionally, assessing the relationship between early onset marijuana use and adult mental 
health can help legislative bodies make important decisions concerning the legalization of 
marijuana within the United States.  
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3. Methods 
 
3.1 Study Sample and Design  
 The data for this thesis analysis was provided by the Substance Abuse and Mental 
Health Services Administration (SAMHSA). The data set used was the National Survey on Drug 
Use and Health (NSDUH), an annual federal survey that is the primary method of data collection 
on illicit drug, alcohol and tobacco use in the US civilian, noninstutionalized population aged 12 
years or older. The NSDUH also includes several modules of questions pertaining to mental 
health. This cross-sectional complex survey has been conducted by SAMHSA since 1971 through 
face-to-face or CAI interviews at the participant’s place of residence. The residences included in 
the survey are private households, noninstutionalized group quarters (shelters, dormitories) 
and military bases. Populations excluded in the survey are the homeless, the institutionalized 
(jails, hospitals) and active duty military. The survey includes a $50 incentive for participants 
and includes respondents from all 50 states and the District of Columbia. Publically availed data 
file for the NSDUH survey from 1979 to 2014 are available on SAMHSA’s website. The specific 
data set analyzed was the publically available 2014 NSDUH SAS file.  
 The NSDUH is sponsored by SAMHSA and the U.S Department of Health and Human 
Services. The survey methodology is planned and managed by SAMHSA’s Center for Behavioral 
Health Statistics and Quality. Data analysis is contracted out and done by RTI International. 
Historically, SAMHSA has presented the NSDUH data in a comprehensive series of reports and 
detailed tables. The detailed tables are split into substance abuse and mental health and 
present corresponding prevalence statistics on characteristics of interest. The reports issued by 
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SAMHSA provide detailed data that focuses on specific topics of interest at the national level. 
Past topics have included substance abuse and mental health treatment utilization, illicit drug 
use prevalence and suicide. State level estimates for all survey questions are available for all 
years the survey was collected.  
3.2 Variables of Interest  
 Variables of interest for this study, along with their presents and a description of what 
they capture are also detailed in Table 1 in the appendix.  
Demographic Variables  
 Five demographic variables of interest were included in the sample analysis and are 
displayed in Table 1 in the Results section. One of the variables, sex (IRSEX) was a dichotomous 
categorical variable and categorized as 1=Male, 2=Female. The remaining four variables were 
categorical, two were modified and two were unmodified. The two modified categorical 
variables were education level (EDUCCAT2) and age (CATAG7). The original levels of education 
were less than high school, high school graduate, some college, college graduate and 12 to 17 
year olds. As mentioned previously, data concerning those under the age of 18 was removed 
from this data subset. The modified education variable did not contain a level for 12 to 17 years 
old. The original age variable levels were 12 to 13 years old, 14 to 15 years old, 16 to 17 years 
old, 18 to 20 years old, 21 to 25 years old, 26 to 34 years old and 35 or older. The modified age 
variable was categorized to 18 to 20 years old, 21 to 25 years old, 26 to 34 years old and 35 or 
older. The remaining categorical variables, race (NEWRACE2) and income (INCOME) maintained 
their original levels in the analysis. The variable race(NEWRACE2) contained levels Non-Hispanic 
White, Non-Hispanic Black/African-American, Non-Hispanic Native American/Alaskan Native, 
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Non-Hispanic Native Hawaiian/Other Pacific Islander, Non-Hispanic Asian, Non-Hispanic more 
than one race and Hispanic. The variable income (INCOME) contained the levels Less than $20, 
000, $20, 000-$49, 999, $50, 000-$74, 999 and $75, 000 or more.  
 
Independent Variable  
 The intendant variable used in this analysis was marijuana age of first use (MJAFU). The 
initial survey questions asked respondents to report their believed first age of marijuana use. 
SAMHSA later recoded the continuous variable into a categorical variable prior to releasing the 
public use data set. The variable marijuana age of first use was used unmodified in its 
categorized recode for this analysis. The categorical levels were 14 years or younger, 15 to 17 
years old, 18 years or older, non-user.  
 
Dependent Variables  
 The three dependent variables used in this analysis were dichotomous categorical 
variables. Two variables, any mental illness (AMIYR_u) and serious mental illness (SMIYR_U) 
were unmodified dichotomous categorical variables with levels 0= no and 1=yes. The variable 
any mental illness(AMIYR_U) captured any mental illness within the past year while the variable 
serious mental illness (MMIYR_U) captured any serious mental illness within the past year. Both 
variables are determined by predictive modeling based on participant’s responses to a 
functional impairment scale and a psychological distress scale included in the NSDUH survey. 
The predictive model produces a variable SMIPP_U, which is then used to determine the 
classification of the respondent. If SMIPP_U is greater than or equal to 0.0192519810, then the 
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respondent is classified as having past year AMI (AMIYR_U=1). If If SMIPP_U is greater than or 
equal to 0.260573529, then the respondent is classified as having past year SMI (SMIYR_U=1). 
The variable adult lifetime major depressive episode (AMDELT) was recoded as a 
dichotomous categorical variable with levels 0=no, 1=yes for ease of analysis.  The original 
levels for AMDELT were 1=yes and 2=no. The depression variable captured lifetime incidence of 
depression as reported by the participant, based on major depressive episode indicators. In 
order to be classified as a “yes”, the participant had to report experiencing at least five out of 
the nine criteria used to define an adult as having had MDE in their lifetime, where at least one 
of the criteria is a depressed mood or loss of interest or pleasure in daily activities.  All 
dependent variables were analyzed using the standard analysis weight, ANALWT_C, as 
recommended by the survey codebook.  
 
3.3 Statistical Analysis 
 All statistical analyses for this study were done in SAS 9.4. The study sample from the 
2014 NSDUH contained 67, 901 participants and had an 81.94% response rate. For the purpose 
of this thesis, analysis was limited to participants 18 and older. This was done in order to 
examine the data that pertained to adults in the survey. After application of this limitation to 
the data, the sample size used for analysis was 41, 285.Missing values of dependent variables 
marijuana age at first use( MJAFU), adult major depressive episode (AMDELT), adult severe 
mental illness in past year(SMIYR_U) and adult any mental illness in past year (AMIYR_U) were 
deleted due to their small cell size.  All variables in the original public use data set that did not 
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pertain to the study sample were dropped for ease of SAS analysis. Figure 1 shows the selection 
process for the study sample.  
The research questions addressed in this analysis were (1) What is the prevalence of 
early onset marijuana use in the United States population?, (2) Does the prevalence of early 
onset marijuana use vary between men and women?, (3) Is there an association between early 
onset marijuana use (<14 years old) and adverse mental health outcomes in adult life? 
Descriptive statistics for this study were conducted using PROC SURVEYFRQ and are detailed in 
Table 1. Descriptive statistics were conducted for gender, race, age, education level and 
income. Rao-Scott chi-square analysis, using the CHISQ option in the SURVEYFREQ procedure, 
was used to identify potential associations and confounders among the demographic variables.  
PROC SURVEYFREQ, was also used to find the prevalence rates for research questions 1 and 2. 
The Rao-Scott  chi-square analysis was also used to determine if there was a statistically 
significant association between the independent variable marijuana age of onset(MJAFU) and 
the selected dependent variables severe mental illness incidence in the past year (SMIYR_U, 
any mental illness incidence in the past year(AMIYR_U) and major depressive episode incidence 
in the past year(AMDELT).   
Multiple logistic regression modeling was then used to examine research question and 
to determine the odds ratios of the associations between the independent variable (MJAFU) 
and the dependent variables (AMDELT, SMIYR_U, AMIYR_U). PRO SURVEY LOGISTIC was used 
to build the logistic regression models.  The NSDUH codebook provided the appropriate weight 
and strata to include when building the logistic regression model. The weight used was 
ANALWT_C and the strata used was VESTR. All analyses were conducted at the α=.05 level of 
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significance. Confounders controlled for in the logistic regression modeling and adjusted odds 
ratios were age, gender, race, education level and income.  
  All analysis was done using SAS 9.4. Demographic and descriptive statistics for the study 
sample are reported in Table 1. The final study sample size was n=41, 285 after those who were 
under the age of 18 at the time or participation were removed from the sample. SAMHSA 
provided weights were used to calculate frequencies and percent’s.  Regarding gender, 48.2% 
of the sample was male and 51.8% of the sample was female. The racial breakdown of the 
sample was 65.4% Non-Hispanic White, 11.7% Non-Hispanic Black, 0.5% Native 
American/Alaskan Native, 0.4% Native Hawaiian/Other Pacific Islander, 5.3% Asian. 1.5% Multi-
Racial and 15.3% Hispanic.  The majority of participants had a high school degree or higher, 
28/9% reported high school graduation while 30.7% reported college graduation. A large 
majority of the sample was 35 or older (69.7%) due in part to the limiting of the study sample to 
respondents aged 18 or older. With respect to yearly income, 18.1% reported %20, 000 or less, 
31% reported $20, 000 to $49, 999, 16.7% reported $50, 000 to $74, 999 and 34.2% reported 
$75, 000 or higher.  
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4. Results 
 
4.1 Descriptive Statistics of Sample  
 
  
 Descriptive statistics pertaining to the sample characteristics by marijuana age of onset 
can be found in Table 2. The final sample size for early onset marijuana users was 4, 321 and 
the final sample size of non-early onset marijuana users was 36, 964. The final weighted 
percent’s were 91.7% non-early onset marijuana users and 8.3% early onset marijuana users. 
Within the study sample (n=41, 285) 4.5 %(95% CI 4.2-4.8) were participants 35 or older who 
reported early onset marijuana use. The second largest age group to report early onset 
marijuana use was ages 26 to 34 years with 2.0%(95% CI 1.8-2.1) of the study sample.  With 
respect to gender males with early onset marijuana use made up 5/1%(95% CI 4.7-5.2), while 
female early onset marijuana users made up 3.3%(95% CI 3.1-3.5). White participants reported 
the highest early onset marijuana use at 5.9%(95% CI 5.6-6.2), while the next largest racial 
group to report early onset marijuana use was Hispanics at 1.1%(85% CI 0.99-1.2). Those who 
were high school graduates and those with some college reported higher rates of early onset 
marijuana use at 2.7%(95% CI 2.5-2.9) and 2.5%(95% CI 2.3-2.7) respectively. Income levels 
were split with similar rates of early onset marijuana use being reported in the $20, 000-$49, 
999 bracket(2.7% 95% CI 2.5-2.9) and the $75, 000 or greater bracket(2.4% 95% CI 2.2-2.6). 
 
4.2 Bivariate Analysis  
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 Rao-Scott analysis was done on demographic characteristics and the independent 
variable (MJAFU) to determine if there was any statistically significant association between the 
two. All demographic variables included (age, gender, race, income and education) were found 
to have a statistical significance with the independent variable marijuana age at first use 
(MJAFU) (p<0.0001). As a result of their statistical significance with the independent variable, 
demographics characteristics were controlled for in later analysis. Table 2 includes the Rao-
Scott chi-square analysis of the demographic variables  
 Rao-Scott chi-square analysis was also performed on the association between the 
independent variable (MJAFU) and the three outcomes of interest, AMDELT, AMIYR_U and 
SMYYR_U). Table 3 displays the conclusions of the chi-square testing of deadened variables. 
The dependent variable any depressive episode in the last year(AMDELT) was found to have a 
statistically significant association with MJAFU (p<0.0001). Both dependent variables addressing 
mental illness (any mental illness in last year and severe mental illness in last year) were also 
found to have a statically significant association with MJAFU (p<0.0001).  
  
4.3 Multivariate Analysis  
 
 Logistic regression was done using the PROC SURVEYLOGISTIC common ad in SAS 9.4 
Both unadjusted and adjusted odds ratios were found for each dependent variable (AMDELT, 
AMIYR_U and SMIYR_U).  Odds ratios are detailed in Tables 4 and 5. Adjusted odds ratios 
accounted for the demographic variables that was significant including age, gender, race, 
income and education level. For the dependent variable any depressive episode in last year 
(AMDELT), early onset marijuana use a significant predictor (AOR=2.133 95% CI 1.906-2.389 
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pp<0.0001). Early onset marijuana was also a significant predictor for severe mental illness in 
the past year (AOR=2.332 95% CI 1.972-2.758 p<0.0001).  Early onset marijuana use also had a 
moderate significance with any mental illness in last year (AOR=1.99 95% CI=1.794-2.208 
p<0.0001).  
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5. Discussion 
 
5.1 Discussion of Research Questions  
 
 The purpose of this thesis was to assess the relationship between early onset marijuana 
use and mental health in adult life. The research questions examined in this study were (1) 
What is the prevalence of early onset marijuana use in the United States population, (2)Does 
the prevalence of early onset marijuana use vary between men and women and (3) Is there an 
association between early onset marijuana use (<14 years old) and adverse mental health 
outcomes in adult life?  This thesis found that in adults aged 18 and older the prevalence of 
early onset marijuana use was 8.3%, a rate relatively similar to the reported early onset 
marijuana use prevalence from the 2013 YRBSS(8.8%)53. This study also found that the 
prevalence of early onset marijuana use does vary in regards to gender, with a prevalence of 
5.1(95% CI 4.7-5.2) for males and 3.3(95% CI 3.1-3.5) for females. The higher prevalence of 
early onset marijuana use in males is consistent with previous research findings in nationally 
representative United States surveys51,53,57.  
    After controlling for race, age, gender, income and education level, all three outcome 
measure for mental illness (serious mental illness, any mental illness and adult depressive 
episode) were associated with the predicting variable early onset of marijuana use( p value < 
0.0001). In individuals who reported an early onset of marijuana use, the crude odds ratio 
showed a twofold increase in past year major depressive episodes compared to the non-early 
onset group (COR=2.107, 95% CI =1.891-2.347, p-value <0.001).  When adjusted for 
demographic characteristics, the odds ratio showed a slightly higher than two fold increase in 
reports of a past year depressive episode (OR=2.133, 95% CI=1.906-2.389, p-vale=<0.001).  
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When early onset marijuana use was used as a predictor for past year serious mental illness 
(SMIYR_U), the adjusted odds ratio found a slightly higher than two fold increase in odds 
(OR=2.332, 95% CI=1.972-2.758, p-value =<.0001). This finding suggests that early onset 
marijuana use has the strong association with serious mental illness in the adult life and could 
be used as a predictor for mental health risk management in the adult population.   The 
statistical association between past year any mental illness (AMIYR_U) and early onset 
marijuana use was milder than the other two dependent variables, those who reported early 
onset use had an adjusted odds ratio of 1.99 compared to those who were not early onset 
users(95% CI=1.794-2.208, p-value=<.0001).   
While past research has shown correlations between marijuana use and acute mental 
illness in adolescents or young adults, few have addressed the effects of early marijuana use on 
adult mental health9,9,56,58. To our knowledge this study is the first to address early onset use of 
marijuana and focus on a population who began using marijuana at the age of 14 or young in a 
nationally representative sample of the U.S. population. These results hold important 
implications for states considering introducing legislature legalizing the use and sale of 
marijuana. The associations between early onset marijuana use and adult mental illness found 
in this study could imply a trajectory for youth raised in states that allow looser access to 
marijuana. Multiple studies have shown the trickledown effect of substance use from adult to 
child, indicating that states where marijuana is legal may have a higher prevalence of youth 
using the drug1. The impact on the population’s future health should be taken into 
consideration when drafting legislature on marijuana use.  
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Additionally, the prevalence of mental health disorders is growing in the United States in 
both the adolescent and adult populations.26,59.Utilizatioon of mental health care is increasing, 
causing a strain on the under developed behavioral health system25. The results of this study 
suggest that clinicians treating mental health disorders in the adult population can assess the 
potential for serious mental illness by determine the age of onset of marijuana use in their 
patient population. These study findings can assist in clinician’s assessment and triage of 
patients with behavior health problems and their potential for more serious mental illness in 
their lifetime due to their early onset marijuana use.  
  
5.2 Study Strengths and Limitations  
 
 This study was conducted using a cross-sectional survey of a nationally representative 
sample of the U.S. population, therefore results of this study are likely generalizable to the U.S. 
The large sample size, both weighted and unweighted allowed for in-depth analysis and strong 
statistical power within the analysis. The data was collected using a computer assisted survey, 
allowing for clarification of the questions and minimal surveyor bias in the sample. The complex 
survey designed allowed for strata and weights to be applied in order to make the sample size 
accurate and statistically strong. The cross-sectional design of the data and this study allows for 
recall bias in the sample, especially when dealing with the independent variable which asked 
the respondent to remember youth activities. The cross-sectional design also did not allow for 
temporality to be established in the analysis of the associations. Additionally, the sensitive 
nature of the survey questions used might have impacted the answers given by participants. 
This study relied on self-reported indicators for mental illness, not diagnosis by DSM-V criteria 
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which may create a bias in accuracy of mental illness in the past year or depressive episodes in 
the past year.  
5.3 Recommendations and Further Research  
 
 Further research should address the limitations in this study, including the lack of 
temporality. A longitudinal cohort study of children that follows them into middle adulthood or 
beyond would provide the temporal type of data needed. Additionally, a cohort study would 
allow for better recall of exact age of first marijuana use and would eliminate much of the recall 
bias present in cross-sectional survey data. Further research should also focus on the 
comorbidities of early onset marijuana use such as alcohol and tobacco use in order to clarify 
the impact of marijuana use.   More accurate diagnostics for mental illness should be used in 
future studies, such as medical records or questions such as “Have you ever been told by an MD 
you have a mental illness?”. The outcomes of this study indicate that states with legal use of 
marijuana should focus on strategies preventing childhood use of the drug and educating the 
population on the impacts of childhood marijuana use.  
 
5.4 Conclusion 
 In conclusion, these findings from a nationally representative sample of U.S. adults aged 
18 and older reveal the positive associations between early onset marijuana use (aged 14 or 
young) and poor mental health outcomes in adult life. Given the findings that early onset 
marijuana use more than doubles the odds of reporting a past year serious mental illness, 
legislations considering legalization of marijuana should take into account the exposure of 
children to the drug. Strategies for the prevention of early onset marijuana use should be 
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established within the U.S. to address this issue. Mental health clinicians should use assessment 
tools to determine if their patient’s are at risk for serious mental illness due to their early onset 
marijuana use.  
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Table 1: Demographic Variables of Interest  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Name  Code Description Levels Percent 
Sex IRSEX Self-reported sex 
at time of survey  
1=Male 
2=Female 
47.62 
52.38 
Education Level EDUCCAT2 Self-reported 
education level at 
time of survey  
1= Less than high 
school 
2= High school 
graduate 
3=Some college 
4=College 
graduate 
5= 12 to 17 years 
old  
10.18 
22.68 
21.65 
20.88 
24.61 
Age CATAG7 Self-reported age 
at time of survey  
1= 12-13 years 
2= 14-15 years  
3= 16-17 years 
4= 18-20 years 
5= 21-25 years 
6= 26-34 years  
7= 30 years or 
older  
7.88 
8.46 
8.27 
8.77 
14.88 
15.18 
35.57 
Race NEWRACE2 Self-reported 
racial/ethnic 
identity  
1= Non-Hispanic 
White 
2= Non-Hospice 
Black/African 
American 
3= Non-Hispanic 
Native 
American/Alaskan 
Native 
4= Non-Hispanic 
Native 
Hawaiian/Other 
Pacific Islander 
5= Non-Hispanic 
Asian 
6= Non-Hispanic 
more than one 
race 
 7= Hispanic  
 
60.67 
12.11 
1.64 
0.54 
4.26 
3.54 
17.23 
Income INCOME Total family 
income in the past 
year 
1= Less than $20, 
000 
2= $20, 000-$49, 
999 
3= $40, 000-$74, 
999 
4+ $75, 000 or 
21.07 
31.01 
16.26 
31.65 
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Table 2.  Descriptive statistics of the analytic sample  
Demographic Variable Frequency 
n =41285 
Percent 
Age   
18-20 4, 782 5.44 
21-25 8, 139 9.08 
26-34 3, 331 15.79 
35 or older 20, 033 69.67 
Gender   
Male 19, 210 48.17 
Female 22, 075 51.83 
Race   
White 25, 832 65.36 
Black/African-American 4, 862 11.71 
Native American/Alaskan Native 669 0.50 
Native Hawaiian/Pacific Islander 220 0.38 
Asian 1, 818 5.24 
Multi-racial 1, 244 1.55 
Hispanic 6, 640 15.27 
Education Level    
< High School  5, 544 13.13 
High School Graduate 12, 389 28.86 
Some College 11, 870 27.29 
College Graduate 11, 482 30.71 
Income Level (U.S. Dollars)   
< 20, 000 9, 129 18.10 
20, 000-49, 999 13, 098 30.98 
50, 000-74, 999 6, 786 16.72 
75, 000 or greater 12, 272 34.20 
Source: National Survey on Drug Use and Health, 2014 
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Table 3.  Chi square results of association between demographic characteristics and early onset marijuana use 
                                                                                Early Onset Use                    Non-Early Onset Use 
Demographic Characteristic  Frequency Weighted 
Percent 
 
Frequency Weighted 
Percent 
 
P-Value 
Age      
    18-20 621 0.7 4161 4.7 <.0001 
    21-25 1033 1.1 7106 8.0  
    26-34 1105 2.0 7226 13.8  
     35 or older 1562 4.5 18471 66.1  
Gender      
     Male 
2413 5.1 
 
16797 43.2 <.0001 
     Female 1908 3.3 20167 48.5  
Race      
      White 2818 5.9 23014 59.5 <.0001 
      Black/African-American 464 0.9 4398 10.8  
      Native American/Alaskan Native 133 0.07 536 0.42  
      Native Hawaiian/Pacific Islander  29 0.3 191 0.34  
      Asian 41 0.08 1777 5.2  
     Multi-racial 214 0.2 1030 1.3  
     Hispanic 622 1.1 6018 14.1  
Education Level      
     < High School  896 1.4 4648 11.7 <.0001 
     High School Graduate 1493 2.7 10896 26.1  
     Some College 1246 2.5 10624 24.8  
     College Graduate 686 1.6 10796 27.2  
Income Level (US Dollars)      
     <20, 000 
1199 1.9 
 
7930 16.2 <.0001 
     20, 000-49, 999 1455 2.7 11643 28.9  
     50, 000-74, 999 662 1.3 6124 15.4  
     75, 000 or greater 1005 2.4 11267 31.8  
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Table 4.  Chi square results of association between dependent variables and early onset marijuana use 
                                                                                           Early Onset Use               Non-Early Onset Use  
                                                                                                  n=4321                                   n=36964 
Dependent Variable Frequency Weighted 
Percent 
Frequency Weighted 
Percent 
P-
Value 
Depressive Episode in Last Year(AMDELT)      
       Yes 
996 1.87 
 
4920 11.07 
 
<.0001 
       No 
3325 6.45 
 
32044 80.61 
 
 
Any Mental Illness in Last Year(AMIYR_U)      
       Yes 
1353 2.17 
 
6956 13.74 
 
<.0001 
       No 
2968 5.84 
 
30008 75.94 
 
 
Severe Mental Illness In Last 
Year(SMIYR_U) 
  
   
      Yes 
397 0.74 
 
1594 3.45 
 
<.0001 
       No 
3924 7.57 
 
35370 88.24 
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Table 5. Odds Ratios of Early Onset Marijuana Use and Indicators of Adult Mental Health 
                                                                                                                           Early Onset Use 
Mental Health Variable OR 95% CI P-Value 
Depressive Episode in Last Year(AMDELT) 2.107 1.891-2.347 
 
<.0001 
Any Mental Illness in Last Year(AMIYR_U) 2.040 1.848-2.252 
 
<.0001 
 
Severe Mental Illness In Last Year(SMIYR_U) 
 
2.497 
 
2.127-2.931 
 
<.0001 
 
 
 
 
 
 
 
 
 
 
Table 6. Adjusted Odds Ratios of Early Onset Marijuana Use and Indicators of Adult Mental Health  
                                                                                                    Early Onset Use                                                       
Mental Health Variable OR 95% CI P-Value 
Depressive Episode in Last Year(AMDELT) 2.133 1.906-2.389 
 
<0.001 
Any Mental Illness in Last Year(AMIYR_U) 1.990 1.794-2.208 
 
<.0001 
 
Severe Mental Illness In Last Year(SMIYR_U) 
 
2.332 
 
1.972-2.758 
 
<.0001 
 
 
 
 
 
 
 
